Tango Therapeutics Sees Surge in Stock Price After Positive Vopimetostat Trial Results and Major Capital Raise

Tango Therapeutics (TNGX) has announced positive data from its Phase 1/2 trial of Vopimetostat (TNG462) in MTAP-deleted cancers and completed a $209.99 million follow-on equity offering and a $15 million private placement. This combination of clinical progress and successful capital raises marks a pivotal step for Tango's research progress and future funding capability. The company's investment narrative now focuses on upcoming trial milestones and the coming end of lock-up agreements in December.